Bimekizumab in Plaque Psoriasis
The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab
in individuals with moderate-to-severe psoriasis who have failed similar therapies.
Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called...
Age: 18 years - 66+
Gender: All
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or...
Age: 18 years - 66+
Gender: All
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive
drug in participants with low body surface area moderate plaque psoriasis and special site
involvement.
Age: 18 years - 66+
Gender: All
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group,
placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 3 doses of
TLL018 as therapy in 120 participants with moderate-to-severe PP.
Age: 18 - 75 years
Gender: All
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
This will be a single-center, open-label clinical study to determine the efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis vulgaris in skin of color (SOC) (FST IV-VI). This study will also evaluate the degree of erythema versus hyperpig...
Age: 18 years - 66+
Gender: All
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
Age: 18 years - 66+
Gender: All
An open-label pilot study to investigate the efficacy of apremilast in the treatment of central centrifugal cicatricial alopecia (CCCA)
"The purpose of this study is to see if the use of apremilast has an effect on the symptoms and progression of central centrifugal cicatricial alopecia (CCCA). Apremilast is an oral PDE4 inhibitor that has anti-inflammatory properties. It inhibits several substances inv...
Age: 18 years - 66+
Gender: Female
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the
efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque
psoriasis of the scalp.
Approximately 300 subjects with moderate to severe plaque psorias...
Age: 18 years - 66+
Gender: All
Psoriasis Longitudinal Assessment and Registry (PSOLAR)
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and
guselkumab in patients with plaque psoriasis, and other all forms of psoriasis (such as
plaque psoriasis and psoriatic arthritis occurring together). The registry study will tr...
Age: 18 - 99 years
Gender: All
Psoriasis Longitudinal Assessment and Registry
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and
guselkumab in patients with plaque and other forms of psoriasis. The study also includes
patients receiving other therapies, such as non-biologic and other biologic agents. T...
Age: 18 - 99 years
Gender: All